Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography–Mass Spectrometry: Challenges, Solutions, Pitfalls, and Future Perspectives
- 10 June 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 32 (8), 1852-1860
- https://doi.org/10.1021/jasms.0c00479
Abstract
Synthetic peptides represent an important and expanding class of therapeutics. Despite having a relatively small size as compared to monoclonal antibodies and other proteins, synthetic peptides are subject to many complex structural modifications originating from the starting materials, manufacturing process, and storage conditions. Although mass spectrometry has been increasingly used to characterize impurities of synthetic peptides, systematic review of this field is scarce. In this paper, an overview of the impurities in synthetic peptide therapeutics is provided in the context of how the knowledge from detailed characterization of the impurities using liquid chromatography-mass spectrometry (LC-MS) can be used to develop the manufacturing process and control strategy for synthetic peptide therapeutics following the critical quality attribute (CQA)-driven and risk-based approach. The thresholds for identifying and controlling the impurities are discussed based on currently available regulatory guidance. Specific LC-MS techniques for identification of various types of impurities based on their structural characteristics are discussed with the focus on structural isomers and stereoisomers (i.e., peptide epimers). Absolute and relative quantitation methods for the peptide impurities are critiqued. Potential pitfalls in characterization of synthetic peptide therapeutics using LC-MS are discussed. Finally, a systematic LC-MS workflow for characterizing the impurities in synthetic peptide therapeutics is proposed, and future perspectives on applying emerging LC-MS techniques to address the remaining challenges in the development of synthetic peptide therapeutics are presented.Keywords
Funding Information
- Eli Lilly and Company
This publication has 43 references indexed in Scilit:
- Analysis of Isoaspartic Acid by Selective Proteolysis with Asp-N and Electron Transfer Dissociation Mass SpectrometryAnalytical Chemistry, 2010
- Identification of Racemization Sites Using Deuterium Labeling and Tandem Mass SpectrometryAnalytical Chemistry, 2010
- Quality specifications for peptide drugs: a regulatory‐pharmaceutical approachJournal of Peptide Science, 2009
- Biomolecule Analysis by Ion Mobility SpectrometryAnnual Review of Analytical Chemistry, 2008
- Formation of Fmoc–β‐alanine during Fmoc‐protections with Fmoc–OSuJournal of Peptide Science, 2008
- Selective separations of peptides with sequence deletions, single amino acid polymorphisms, and/or epimeric centers using macrocyclic glycopeptide liquid chromatography stationary phasesJournal of Chromatography A, 2004
- Synthesis of ‘difficult’ peptide sequences: application of a depsipeptide technique to the Jung–Redemann 10- and 26-mers and the amyloid peptide Aβ(1–42)Tetrahedron Letters, 2004
- Selective separations of peptides with sequence deletions, single amino acid polymorphisms, and/or epimeric centers using macrocyclic glycopeptide liquid chromatography stationary phasesJournal of Chromatography A, 2004
- Large-scale manufacture of peptide therapeutics by chemical synthesisNature Reviews Drug Discovery, 2003
- Peptide chiral purity determination: hydrolysis in deuterated acid, derivatization with Marfey's reagent and analysis using high-performance liquid chromatography-electrospray ionization-mass spectrometryJournal of Chromatography A, 1995